Search

in press

Purpose To evaluate B-mode ultrasound (B-US) and contrast-enhanced ultrasound (CEUS) patterns of focal splenic incidentalomas (FSIs), and to correlate ultrasound patterns with benignity and malignancy via histologic examination and/or the clinical course. Materials and Methods Between 2004 and 2021, 139 consecutive patients with an FSI detected by B-US were investigated additionally with CEUS. On CEUS, the arterial enhancement (AE) of the FSI (hyperenhancement, isoenhancement, hypoenhancement, and absent enhancement) was analyzed. Subsequently, the malignancy rate according to different B-US echo patterns and CEUS perfusion patterns was determined. Results The final diagnosis of FSI was malignant in 9/139 (6.5%) and benign in 130/139 (93.5%) cases. The hypoechoic and hyperechoic lesions on B-US with arterial hyperenhancement on CEUS and the echogenic cystic or complex lesions on B-US with predominantly absent enhancement on CEUS were benign in 54/54 (100%) cases. 6/37 (16.2%) hypoechoic lesions on B-US with arterial hypo-/isoenhancement on CEUS and 3/48 (6.3%) of hyperechoic lesions on B-US with an arterial hypo-/isoenhancement on CEUS were malignant. Conclusion Based on these results, FSIs reveal different malignancy rates depending on the B-US und CEUS patterns, and classification according to these B-US and CEUS patterns may be helpful in further evaluation of an FSI.

AIMS: Although acute heart failure (AHF) with volume overload is treated with loop diuretics, their dosing and type of administration are mainly based upon expert opinion. A recent position paper from the Heart Failure Association (HFA) proposed a step-wise pharmacologic diuretic strategy to increase the diuretic response and to achieve rapid decongestion. However, no study has evaluated this protocol prospectively. METHODS AND RESULTS: The Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure (ENACT-HF) study is an international, multicentre, non-randomized, open-label, pragmatic study in AHF patients on chronic loop diuretic therapy, admitted to the hospital for intravenous loop diuretic therapy, aiming to enrol 500 patients. Inclusion criteria are as follows: at least one sign of volume overload (oedema, ascites, or pleural effusion), use=40mg of furosemide or equivalent for >1month, and a BNP>250ng/L or an N-terminal pro-B-type natriuretic peptide>1000pg/L. The study is designed in two sequential phases. During Phase 1, all centres will treat consecutive patients according to the local standard of care. In the Phase 2 of the study, all centres will implement a standardized diuretic protocol in the next cohort of consecutive patients. The protocol is based upon the recently published HFA algorithm on diuretic use and starts with intravenous administration of two times the oral home dose. It includes early assessment of diuretic response with a spot urinary sodium measurement after 2h and urine output after 6h. Diuretics will be tailored further based upon these measurements. The study is powered for its primary endpoint of natriuresis after 1day and will be able to detect a 15% difference with 80% power. Secondary endpoints are natriuresis and diuresis after 2days, change in congestion score, change in weight, in-hospital mortality, and length of hospitalization. CONCLUSIONS: The ENACT-HF study will investigate whether a step-wise diuretic approach, based upon early assessment of urinary sodium and urine output as proposed by the HFA, is feasible and able to improve decongestion in AHF with volume overload.

INTRODUCTION To describe the value of contrast-enhanced ultrasound (CEUS) for the differentiation of malignant from benign parietal pleural lesions (PPLs). MATERIALS AND METHODS From November 2005 to June 2019, 63 patients with histologically/cytologically confirmed PPLs were investigated by CEUS. On CEUS, the extent of enhancement (EE; marked or reduced/absent) and the homogeneity of enhancement (HE; homogeneous or inhomogeneous) were analyzed retrospectively. RESULTS In total, 24/63 lesions were benign, and 39/63 lesions were malignant. On CEUS, 11/24 benign and 36/39 malignant lesions showed a marked enhancement. A marked enhancement was significantly more frequently associated with malignancy compared with benign lesions (p

ZusammenfassungDas Immundefizienzsyndrom der funktionellen Hyposplenie/Asplenie ist weitgehend unerkannt. Die Goldstandardprozedur stellt die Technetium-99m-Szintigrafie von hitzedenaturierten Erythrozyten (TSZ) sowie der Nachweis von pitted Erythrozyten oder Howell-Jolly-Körperchen (HJB) dar. Erste Arbeiten weisen darauf hin, dass dieses Krankheitsbild mit einer kleinen Milz assoziiert ist. Ziel der vorliegenden Übersicht ist es, den Stellenwert der B-Bild-Sonografie und der kontrastunterstützten Sonografie bei der Immunschwäche der Hyposplenie darzustellen.

The immunodeficiency syndrome of functional hyposplenia/asplenia is frequently unrecognized. The gold standard procedure for the diagnosis of this disease is technetium-99m scintigraphy of heat-denatured erythrocytes and the detection of pitted erythrocytes or Howell-Jolly bodies. Initial work suggests that this clinical presentation is associated with a small spleen. The aim of this review is to describe the value of B-mode and contrast-enhanced ultrasound in the identification of immunodeficiency caused by functional hyposplenism.Das Immundefizienzsyndrom der funktionellen Hyposplenie/Asplenie ist weitgehend unerkannt. Die Goldstandardprozedur stellt die Technetium-99m-Szintigrafie von hitzedenaturierten Erythrozyten (TSZ) sowie der Nachweis von pitted Erythrozyten oder Howell-Jolly-Körperchen (HJB) dar. Erste Arbeiten weisen darauf hin, dass dieses Krankheitsbild mit einer kleinen Milz assoziiert ist. Ziel der vorliegenden Übersicht ist es, den Stellenwert der B-Bild-Sonografie und der kontrastunterstützten Sonografie bei der Immunschwäche der Hyposplenie darzustellen.

To describe the vascularization of peripheral lung carcinoma in CEUS and to compare with B-mode ultrasound (US) and clinical data. From April 2004 until September 2015, n = 89 patients with peripheral lung carcinoma were investigated by B-mode US and CEUS. The extent (EE: hypoechoic, hyperechoic), homogeneity (HE: homogeneous, inhomogeneous) and time of enhancement (TE) have been defined. Early pulmonary-arterial enhancement (PA) before contrast floating to the thoracic wall was differentiated from simultaneous or delayed bronchial-arterial enhancement (BA). CEUS parameters were compared by B-mode US and histology. n = 25 patients had early PA enhancement (TE: 8 ± 3.7 s), and n = 64 (72 %) had simultaneous/delayed BA enhancement (TE: 17.6 ± 6.2 s) (p 0.001). PA enhancement (EE/HE) was hyperechoic (n = 11/25), homogeneous (n = 11/25) and showed an air bronchogram more often (n = 11/17, p 0.001). BA enhancement (EE/HE) was frequently hypoechoic (n = 34/64) and inhomogeneous (n = 54/64). BA enhancement was associated with necrosis (n = 36/42, p = 0.009). PA and BA enhancement distributed to different histologies: n = 42 adenocarcinomas (18 PA, 24 BA), n = 30 squamous cell carcinomas (4 PA, 26 BA), n = 13 other types of NSCLC (3 PA, 10 BA), and n = 4 SCLC (0 PA, 4 BA) (p = 0.016). The vascularization of peripheral lung carcinomas is heterogeneous and is influenced by histology. In this study, lung carcinomas are predominantly supplied by bronchial arteries, whereas a part of adenocarcinomas and non-adenocarcinomas show PA enhancement.ZIEL: Beschreibung von B-Bild-Ultraschall (US) und CEUS-Mustern peripherer Lungenkarzinome mittels CEUS in Bezug zu Histologie und klinischen Parametern. Im Zeitraum von April 2004 bis September 2015 wurden n = 89 Patienten mit histologisch gesichertem peripherem Lungenkarzinom im B-Bild-US und CEUS untersucht. In der CEUS wurden Ausmaß (EE: hypoechogen, hyperechogen), Homogenität (HE: homogen, inhomogen) und die Zeit zum Enhancement (TE) bestimmt. Ein vorzeitiges pulmonal-arterielles Enhancement (PA) wurde im Vergleich zur Thoraxwand von einem zeitgleichen bronchial-arteriellen Enhancement (BA) unterschieden. CEUS-Daten wurden mit B-Bild-US und Histologie verglichen. n = 25 Patienten (28 %) hatten ein vorzeitiges PA-Enhancement (TE: 8 ± 3,7 s), n = 64 (72 %) ein zeitgleiches BA-Enhancement (TE: 17,6 ± 6,2 s) (p 0,001). Das PA-Enhancement (EE/HE) war hyperechogen (n = 11/25), homogen (n = 11/25) und zeigte im B-Bild-US häufiger ein Aerobronchogramm (n = 11/17, p 0,001). Das BA-Enhancement (EE/HE) war bevorzugt hypoechogen (n = 34/64) und inhomogen (n = 54/64). Bei einem BA-Enhancement fanden sich häufiger Nekrosen (n = 36/42, p = 0,009). PA- und BA-Enhancement verteilten sich in den unterschiedlichen Histologien: n = 42 Adenokarzinome (18 PA, 24 BA), n = 30 Plattenepithelkarzinome (4 PA, 26 BA), n = 13 sonstige NSCLC (3 PA, 10 BA) und n = 4 SCLC (0 PA, 4 BA) (p = 0,016). Die Vaskularisation von peripheren Lungenkarzinomen ist heterogen und wird durch die Histologie beeinflusst. Es zeigt sich neben einer vorherrschend bronchial-arteriellen Versorgung von malignen Lungentumoren auch ein Anteil von Adenokarzinomen und Nicht-Adenokarzinomen, die ein PA-Enhancement aufweisen.